The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

References

• Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524–536.
   PubMed Web of Science ®Google Scholar
• Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res. 2012;2012:230624.
   PubMed Web of Science ®Google Scholar
• Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019 Jan;35(1):e3070.
   PubMed Web of Science ®Google Scholar
• Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993 Sep 15;268(26):19650–19655.
   PubMed Web of Science ®Google Scholar
• Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009 May;11(5):498–505.
   PubMed Web of Science ®Google Scholar
• Retterstøl K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs. 2009 Sep;18(9):1405–1411.
   PubMed Web of Science ®Google Scholar
• Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011 Jun;96(6):1695–1702.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008 Oct 4;372(9645):1240–1250.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012 Dec;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009 Dec;25(12):3049–3057.
   PubMed Web of Science ®Google Scholar
• Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016 May;55(5):625–634.
   PubMed Web of Science ®Google Scholar
• Yoon KH, Kang J, Kwon SC, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020 Aug;22(8):1292–1301.
   PubMed Web of Science ®Google Scholar
• Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother. 2017 Apr;18(6):555–571.
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493.
   PubMed Web of Science ®Google Scholar
• Ingwersen SH, Petri KC, Tandon N, et al. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with type 2 diabetes from China, India and South Korea. Diabetes Res Clin Pract. 2015;108(1):113–119.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Carlsson Petri KC, Ingwersen SH, Flint A, et al. Semaglutide s.c. once-weekly in type 2 diabetes: a population pharmacokinetic analysis. Diabetes Ther. 2018 Aug;9(4):1533–1547.
   PubMed Web of Science ®Google Scholar
• Bucheit JD, Pamulapati LG, Carter N, et al. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther. 2020 Jan;22(1):10–18.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Heise T, Birman P, et al. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156–1164.
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15;62(2):173–181.
   PubMed Web of Science ®Google Scholar
• Ingwersen SH, Khurana M, Madabushi R, et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012 Dec;52(12):1815–1823.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the pioneer 3 randomized clinical trial. Jama. 2019 Apr 16;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Torekov SS, Kipnes MS, Harley RE, et al. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab. 2011 Jul;13(7):639–643.
   PubMed Web of Science ®Google Scholar
• Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003 Nov;307(2):490–496.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015 Sep 24;58(18):7370–7380.
   PubMed Web of Science ®Google Scholar
• Lv J, Pan Y, Li X, et al. The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide. PLoS One. 2014;9(5):e96833.
   PubMed Web of Science ®Google Scholar
• Okechukwu CE. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021 Aug 5;385(6):572–573.
   PubMedGoogle Scholar
• Jensen SBK, Janus C, Lundgren JR, et al. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022 Aug 15;13(1):4770.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj. 2012 Jan;10(344):d7771.
   Google Scholar
• Cantini G, Mannucci E, Luconi M. Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol Metab. 2016 Jun;27(6):427–438.
   PubMed Web of Science ®Google Scholar
• Caruso I, Cignarelli A, Laviola L, et al. GLP-1 receptor agonists for cardiovascular protection: a matter of time. Diabetes Care. 2022 Feb 1;45(2):e30–e31.
   PubMed Web of Science ®Google Scholar
• Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials. Trends Endocrinol Metab. 2019 Sep;30(9):578–589.
   PubMed Web of Science ®Google Scholar
• MS AEA, Kahle M, JJ M, et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017 Feb;19(2):216–227.
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 2001 Dec;25(Suppl 5):S42–7.
   PubMedGoogle Scholar
• Trapp S, Brierley DI. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br J Pharmacol. 2022 Feb;179(4):557–570.
   PubMed Web of Science ®Google Scholar
• Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014 Sep;15(3):181–187.
   PubMed Web of Science ®Google Scholar
• Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015 6;Jun(3):109–134.
   Google Scholar
• Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jun;88(6):2719–2725.
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009 Jul 4;374(9683):39–47.
   PubMed Web of Science ®Google Scholar
• Simons-Linares CR, Elkhouly MA, Salazar MJ. Drug-induced acute pancreatitis in adults: an update. Pancreas. 2019 Nov;48(10):1263–1273.
   PubMed Web of Science ®Google Scholar
• Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabet Med. 2013 Oct;30(10):1148–1155.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kaye JA, Cai Z, et al. Area postrema cell types that mediate nausea-associated behaviors. Neuron. 2021 Feb 3;109(3):461–472.e5.
   PubMed Web of Science ®Google Scholar
• Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology. 2009 Apr;150(4):1680–1687.
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, DeFronzo RA, Gastaldelli A, et al. Glucagon-like peptide-1 and the central/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab. 2017 Feb;28(2):88–103.
   PubMed Web of Science ®Google Scholar
• Christensen RM, Juhl CR, Torekov SS. Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists. Drug Saf. 2019 Aug;42(8):957–971.
   PubMed Web of Science ®Google Scholar